Steering Committee

Marco Prosdocimi, Ph.D.

Pubblicato il

Marco is Managing Director of Rare Partners since its foundation in March 2010. He collaborates as a consultant with Pharmaceutical Companies, with Investment Funds and with Research Organizations since 1996, focusing his activity in the areas of Research & Development. Prior to this he rose to Research & Development Director at Fidia Research Laboratories during […]

Consiglio Direttivo

Marco Prosdocimi

Pubblicato il

Marco ricopre la funzione di Managing Director di Rare Partners dalla sua fondazione nel mese di Marzo 2010. Collabora come consulente con aziende farmaceutiche, con fondi di investimento e con organizzazioni di ricerca dal 1996, con particolare riguardo per l’area Ricerca & Sviluppo.In precedenza ha sviluppato la propria carriera, sino al ruolo di Direttore Ricerca e Sviluppo, […]

Research projects

TMA project

Pubblicato il

Last generation 4,6,4′- trimethylangelicin (TMA) – derivatives with anti-inflammatory properties  Correction of the defective CFTR protein is the priority goal in the treatment of the lung pathology of patients affected by cystic fibrosis. The possibility that mutated CFTR correctors and potentiators currently in clinics are sufficient to intervene on the chronic inflammatory status of CF […]

Research projects

MCU project

Pubblicato il

mitochondria as central hub of pulmonary inflammation in cystic fibrosis The ideal drug or treatment for cystic fibrosis (CF) should be one that rescues and potentiates the residual functionality of defective CF Transmembrane conductance Regulator (CFTR) channel, but also generates favourable conditions to interrupt the vicious circle that sustains lung hyperinflammation generated by chronic bacterial infection and […]

Research projects

PNA project

Pubblicato il

Peptide-nucleic acids for CFTR correction MicroRNAs as key post-transcriptional regulators of gene expression. MicroRNAs (miRNAs) are a family of small (19 to 25 nucleotides in length) noncoding RNAs that regulate gene expression by sequence-selective targeting of mRNAs, leading to a translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and the […]

Research projects

BSS project

Pubblicato il

when old drugs learn new tricks: betasitosterol (BSS) from traditional medicine to anti-inflammatory molecular therapy: a safe pharmaceutical repurposing By serendipity, looking at the amazingly positive clinical response in a native-Morrocan child affected by a chronic inflammatory lung disease when she was assuming per os the “black seeds from North-Africa deserts”, a traditional remedy utilized for […]

Uncategorized

Giulio Cabrini, M.D.

Pubblicato il

Doctor in Medicine at the School of Medicine of the University of Padova, IT (1979) and trained at the Institute of General Pathology of the University of Verona, IT, and the Laboratory of Membrane Biophysics of the University of California San Francisco, CA, U.S.A. (1982-1986), he founded and directed the Laboratory of Molecular Pathology of […]

Progetti di ricerca

Progetto BSS

Pubblicato il

il betasitosterolo dalla medicina tradizionale alla terapia molecolare anti-infiammatoria: how old drugs learn new tricks ovvero riposizionamento farmaceutico avanzato e in sicurezza Per puro caso, osservando la risposta clinica positiva in una bambina originaria del Marocco affetta da patologia infiammatoria cronica polmonare trattata per os con i “semi neri del deserto nord-africano” macinati e dispersi […]

Progetti di ricerca

Progetto TMA

Pubblicato il

la famiglia chimica delle furocumarine: modellistica molecolare per nuovi farmaci anti-infiammatori La correzione della proteina CFTR mutata è l’obiettivo prioritario del trattamento della patologia polmonare dei pazienti affetti da fibrosi cistica. La possibilità che “correttori” e “potenziatori” della CFTR mutata siano in grado di curare contemporaneamente anche la componente infiammatoria cronica polmonare non è confermata […]